Form 13-F position report

NGM BIOPHARMACEUTICALS INC

Reported by VANGUARD GROUP INC

NGM CUSIP 62921N105 Manager CIK 0000102909

Reported 0 shares, down 2,324,392 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 21 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 65160000
2021-06-30 27392000
2021-09-30 32794000
2021-12-31 52550000
2022-03-31 45971000
2022-06-30 43629000
2022-09-30 51003000
2022-12-31 22535528
2023-03-31 15008374
2023-06-30 7234544
2023-09-30 2954378
2023-12-31 2379923
2024-03-31 3695783
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for NGM BIOPHARMACEUTICALS INC held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Reduced 0 -2,324,392 (-100.0%) 0 $0 2024-08-13
Q1 2024 Reduced 2,324,392 -446,182 (-16.1%) < 0.01% $3,695,783 2024-05-10
Q4 2023 Added 2,770,574 +9,472 (0.3%) < 0.01% $2,379,923 2024-02-14
Q3 2023 Reduced 2,761,102 -32,158 (-1.2%) < 0.01% $2,954,378 2023-11-14
Q2 2023 Reduced 2,793,260 -885,263 (-24.1%) < 0.01% $7,234,544 2023-08-14
Q1 2023 Reduced 3,678,523 -810,626 (-18.1%) < 0.01% $15,008,374 2023-05-15
Q4 2022 Added 4,489,149 +589,852 (15.1%) < 0.01% $22,535,528 2023-02-10
Q3 2022 Added 3,899,297 +496,089 (14.6%) < 0.01% $51,003,000 2022-11-14
Q2 2022 Added 3,403,208 +388,733 (12.9%) < 0.01% $43,629,000 2022-08-12
Q1 2022 Added 3,014,475 +47,238 (1.6%) < 0.01% $45,971,000 2022-05-13
Q4 2021 Added 2,967,237 +1,407,112 (90.2%) < 0.01% $52,550,000 2022-02-14
Q3 2021 Added 1,560,125 +171,051 (12.3%) < 0.01% $32,794,000 2021-11-12
Q2 2021 Reduced 1,389,074 -852,374 (-38.0%) < 0.01% $27,392,000 2021-08-13
Q1 2021 Added 2,241,448 +485,187 (27.6%) < 0.01% $65,160,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

74 managers reported NGM BIOPHARMACEUTICALS INC for Q2 2024.

Managers reporting NGM BIOPHARMACEUTICALS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 0 -3,004,210 0 $0 21 qtrs
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM Reduced 0 -4,381 0 $0 21 qtrs
EXCHANGE TRADED CONCEPTS LLC Reduced 0 -186,232 0 $0 5 qtrs
GSA CAPITAL PARTNERS LLP Reduced 0 -33,529 0 $0 8 qtrs
NEW YORK STATE COMMON RETIREMENT FUND Reduced 0 -10,252 0 $0 21 qtrs
Engineers Gate Manager LP Reduced 0 -22,269 0 $0 4 qtrs
NISA INVESTMENT ADVISORS LLC Reduced 0 -75 0 $0 20 qtrs
NATIXIS Reduced 0 -181,366 0 $0 2 qtrs
STATE STREET CORPORATION Reduced 0 -823,111 0 $0 21 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 0 -983,836 0 $0 21 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 13, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.